Levemir Flextouch

Insulin Detemir, the active ingredient in Levemir Flextouch, is a long‑acting insulin analog presented as an injectable solution for subcutaneous use. It provides basal insulin coverage to control blood glucose levels in individuals with type 1 or type 2 diabetes mellitus, helping to maintain glycemic stability throughout the day.

GNH USA supplies Levemir Flextouch as a licensed, GDP‑compliant international pharmaceutical product, delivering the medication to hospitals, pharmacies and clinics worldwide in accordance with EU regulatory standards.

Levemir Flextouch is a basal insulin analog that acts on the endocrine system to manage chronic hyperglycaemia in diabetes.

- Type 1 diabetes mellitus: provides long‑acting insulin to maintain fasting glucose levels. - Type 2 diabetes mellitus: supplies basal insulin to complement oral agents and improve overall glycaemic control. - Diabetes requiring basal insulin supplementation: offers steady insulin exposure to reduce daily glucose excursions.

Levemir Flextouch may be associated with several adverse reactions.

Common Side Effects: - Hypoglycaemia: low blood glucose episodes, especially if meals are missed or dosing is excessive. - Injection‑site reactions: redness, swelling, or itching at the injection site. - Weight gain: modest increase in body weight with chronic use. - Lipodystrophy: localized changes in subcutaneous fat with repeated injections. - Edema: mild peripheral swelling in some patients. - Headache: occasional mild headache.

Serious or Rare Side Effects: - Severe hypoglycaemia: can lead to seizures, loss of consciousness, or injury. - Allergic reactions: rash, urticaria, or angioedema. - Anaphylaxis: rare but life‑threatening systemic hypersensitivity. - Insulin antibody formation: may alter insulin effectiveness. - Hypokalemia: low potassium levels in rare cases. - Severe injection‑site necrosis: very uncommon tissue damage.

When using Levemir Flextouch, several safety considerations are important.

- Hypoglycaemia risk: monitor blood glucose regularly and adjust dose as needed. - Renal impairment: consider dose reduction and close monitoring in patients with reduced kidney function. - Pregnancy: use only if the expected benefit outweighs potential risk to the fetus. - Elderly patients: initiate therapy at a low dose and titrate cautiously. - Concomitant beta‑blockers: may mask hypoglycaemia symptoms, requiring vigilant glucose checks. - Storage: Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Levemir Flextouch can interact with several medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Beta‑blockers: may conceal hypoglycaemia warning signs. - MAO inhibitors: can potentiate insulin’s glucose‑lowering effect. - Alcohol: may enhance insulin action and increase hypoglycaemia risk.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may raise blood glucose, requiring dose adjustment. - Corticosteroids: can increase insulin requirements. - ACE inhibitors: may affect potassium balance, necessitating monitoring. - Oral contraceptives: may slightly alter insulin sensitivity. - NSAIDs: high doses may affect renal function and insulin clearance.